Skip to main content
Premium Trial:

Request an Annual Quote

Thermo s Revenues Grow 7 Percent in Q1; Profit Jumps 13 Percent

NEW YORK, April 27 (GenomeWeb News) - Thermo Electron today reported a 7-percent increase in revenues and a 13-percent jump in earnings for the first quarter of 2005.


Revenues for the three month period ended March 31 grew to $559.2 million from $525 million during the same period in 2004. Most of this increase resulted from acquisitions, according to the company. Thermo's Life and Laboratory Sciences unit, which also sells mass spectrometers for proteomics, had $393.3 million in revenues, an 8-percent increase from $365.5 million during the year-ago quarter.


R&D expenses in the period almost doubled to $7.4 million from $3.8 million during last year's first quarter.


Thermo's net income for the quarter grew to $48.9 million, or $.30 per share, up from $43.1 million, or $.26 per share, during the same quarter last year.


As of April 2, Thermo had $351.6 million in cash and cash equivalents, and $177 million in short-term available-for-sale investments.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.